Vestura
Product Images NDC 0093-4000

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Vestura (NDC 0093-4000). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 1)

A horizontal forest plot showing hazard ratios, rate ratios, and odds ratios from various studies including Ingenix, EURAS, LASS, FDA-funded study, Danish study and re-analysis, MEGA study, German case-control, PharMetrics, and GPRD study. The graph includes confidence intervals and groups studies into categories such as prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic cases only.*

FDA Label Image

Figure 2 (Image 2)

A bar chart showing the number of women with a blood clot out of 10,000 women years (WY) for different groups: Non-Pregnant Non-COC users (range 1 to 5), COC users (range 3 to 9), Pregnant women (range 5 to 20), and Postpartum women (12 weeks only) with the highest range from 40 to 65.*

FDA Label Image

Structural Formula (Image 3)

Chemical structures of the active ingredients Drospirenone and Ethinyl Estradiol as labeled, representing their molecular configurations in USP form.*

FDA Label Image

Chart (Image 4)

Diagram illustrating pregnancy likelihood associated with different birth control methods. The vertical arrow denotes fewer to more pregnancies per 100 women per year. Methods with fewer pregnancies include implants, injections, intrauterine devices, and sterilization, followed by birth control pills, skin patch, and vaginal ring with hormones. Condoms and diaphragm have moderate pregnancy rates. Methods with higher pregnancy rates include no sex on fertile days, spermicide, and withdrawal. No birth control shows the highest pregnancy rate.*

FDA Label Image

Blister (Image 5)

Blister pack of Vestura tablets containing drospirenone and ethinyl estradiol USP 3 mg/0.02 mg. The pack is organized by day of the week over four weeks, with circular tablet compartments labeled for Sunday through Saturday. Instructions indicate to start at week 1 and follow arrows. NDC 0093-4000-28 is printed on the right side. No manufacturer logo is visible.*

FDA Label Image

Likelihood Of Developing A Serious Blood Clot (Image 6)

A horizontal bar chart showing the likelihood of developing a serious blood clot among different groups of women. Categories include Non-Pregnant Non-COC users, COC users, Pregnancy, and Postpartum (12 weeks only). The x-axis measures the number of women with a blood clot per 10,000 women years, ranging from 0 to 70. Estimated risk ranges are indicated for each group, with postpartum having the highest range (40 to 65) and non-pregnant non-COC users the lowest (1 to 5). A note explains pregnancy data and model assumptions.*

FDA Label Image

Carton (Image 7)

Packaging label for Vestura (drospirenone and ethinyl estradiol) tablets USP 3 mg/0.02 mg by Teva Pharmaceuticals USA, Inc. The label indicates a 28-day regimen with 3 tablet dispensers, each containing 28 tablets. It features the Teva logo, NDC 0093-4000-62, and the Shaping Women's Health emblem.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.